Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024
Reviva Pharmaceuticals (NASDAQ: RVPH) announced it will present positive speech latency data for brilaroxazine in schizophrenia from their Phase 3 RECOVER trial at the CNS Summit 2024.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Reviva Pharmaceuticals (NASDAQ: RVPH) announced it will present positive speech latency data for brilaroxazine in schizophrenia from their Phase 3 RECOVER trial at the CNS Summit 2024. The presentation titled 'Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine' will be delivered as a poster presentation by Dr. Jan Sedway from WCG Clinical on November 12th in Boston, Massachusetts.
Positive
- Positive speech latency data from Phase 3 RECOVER trial to be presented
- Study demonstrates enhanced treatment effects for brilaroxazine in schizophrenia
Negative
- None.
Details
News Market Reaction – RVPH
The recorded move for RVPH in the trading session of this news was +1.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2024, taking place November 10-13, in Boston, Massachusetts.
Details for the poster presentation can be found below:
Title: Enrichment Based on Speech Latency Enhances Treatment Effects in a Phase III Study of Brilaroxazine
Poster Board: 10
Date and Time: Tuesday, November 12th from 5:00 - 7:00 PM ET
Presenter: Dr. Jan Sedway, WCG Clinical
Abstracts and additional details can be found at the CNS Summit 2024 website.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.